OBSERVED COMPLICATIONS FROM DEXAMETHASONE INTRAVITREAL IMPLANT FOR THE TREATMENT OF MACULAR EDEMA IN RETINAL VEIN...

Area of Science:

• Ophthalmology
• Retinal Diseases
• Pharmacology

Background:

• Retinal vein occlusion (RVO) causes macular edema, impacting vision.
• Intravitreal dexamethasone implant (IDI) is a treatment option for RVO-related macular edema.
• Understanding adverse events associated with IDI is crucial for patient management.

Purpose of the Study:

• To evaluate adverse events, specifically intraocular pressure (IOP) changes and cataract surgery incidence, following IDI treatment for RVO-induced macular edema.
• To analyze these events across multiple treatment rounds and in specific patient subgroups.

Main Methods:

• Retrospective review of 61 eyes treated with IDI for RVO-induced macular edema.
• Data collected at baseline, 2, and 6 months post-treatment.
• Outcomes included IOP measurements, need for IOP management, and cataract surgery rates; subgroup analysis by RVO type and glaucoma status was performed.

Main Results:

• 12% of eyes experienced IOP >25 mmHg; 11% required medical IOP management.
• Cataract surgery was required in 24% of phakic eyes, increasing with repeated implants.
• Higher IOP was noted in central RVO and glaucoma/ocular hypertension subgroups.

Conclusions:

• IOP elevation is most pronounced 2 months post-implant.
• Repeated IDI treatments do not elevate IOP risk if initial treatments are tolerated.
• Patients with central RVO and glaucoma/ocular hypertension face higher IOP-related risks; repeated treatments significantly increase cataract surgery incidence.